Patents
Literature
2 results about "Oestrogen receptor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and analogous compounds as cyp11a1 inhibitors for the treatment of prostate cancer
The present invention relates to compounds of formula (I) wherein A is a 3-10 membered carbocyclic ring or a 4-12 membered heterocyclic ring containing 1-4 heteroatoms selected from O, N or S; B is any one of the following groups (1), (2) or (3); C is any one of the following groups (1'), (2'), (3') or (4'); G1 is CH2, NH or O; G2 and G3 are independently of each other CH or N; Z is -C(O)-, -SO2-, -C 1‑3 alkyl- or -CH2-C(O)-; L is a bond, -C 1‑7 alkyl- or -C 1‑7 alkenyl-. The compounds of formula (I) are inhibitors of cytochrome P450 monooxygenase 11A1 (CYP11A1). The compounds are useful as medicaments for the treatment of steroid receptor, e.g. androgen receptor or estrogen receptor dependent diseases and disorders such as cancer including prostate cancer and estrogen cancer.
![2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and analogous compounds as cyp11a1 inhibitors for the treatment of prostate cancer](https://images-eureka.patsnap.com/patent_img/11b7d4da-8984-4477-b1aa-15fd7bf9c345/QLYQS_1.png "2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and analogous compounds as cyp11a1 inhibitors for the treatment of prostate cancer")
![2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and analogous compounds as cyp11a1 inhibitors for the treatment of prostate cancer](https://images-eureka.patsnap.com/patent_img/11b7d4da-8984-4477-b1aa-15fd7bf9c345/QLYQS_2.png "2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and analogous compounds as cyp11a1 inhibitors for the treatment of prostate cancer")
![2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and analogous compounds as cyp11a1 inhibitors for the treatment of prostate cancer](https://images-eureka.patsnap.com/patent_img/11b7d4da-8984-4477-b1aa-15fd7bf9c345/QLYQS_3.png "2,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and analogous compounds as cyp11a1 inhibitors for the treatment of prostate cancer")
Owner:ORION CORP(FI)
Combination therapy for treatment of cancer
PCT designated stageWO2026112410A1Organic active ingredientsAntineoplastic agentsOestrogen receptorOncology
Disclosed are novel compounds for use in treating a proliferative disorder such as a cancer. Further disclosed are compositions comprising the novel compounds. Methods of using the disclosed compounds and compositions are further described. The methods include administering one or more of the disclosed compounds for treatment of various proliferative disorders, including an HRAS-driven cancer, a KRAS-driven cancer, a NRAS-driven cancer, Ewing sarcoma, B-cell acute lymphoblastic leukemia, leukemia, lung cancer, non-small cell lung cancer (NSCLC), solid tumor, breast cancer, triple-negative breast cancer (TNBC), hormone-resistant triple negative breast cancer. Further described are combination therapies in which a novel compound is administered in combination with one or more of a MEK inhibitor, a KRAS G12C inhibitor, or a Selective Estrogen Receptor Degrader (SERD) to an individual in need thereof.
Owner:CHILDRENS HOSPITAL MEDICAL CENT CINCINNATI